Core Viewpoint - The company has entered into an exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. for the development and commercialization of LAE002 (afuresertib) in the Chinese region, which includes mainland China, Hong Kong, Macau, and Taiwan [1] Group 1: Licensing Agreement Details - The licensing agreement grants Qilu Pharmaceutical exclusive rights to research, develop, and commercialize LAE002 in the specified regions [1] - The company will be responsible for completing the Phase III clinical trial for HR+/HER2- breast cancer [1] Group 2: Financial Terms - The company is entitled to receive a total of up to RMB 530 million in non-refundable upfront and clinical development milestone payments until the first indication receives new drug application approval in China [1] - The maximum total upfront and milestone payments the company can receive under the licensing agreement is RMB 2.045 billion [1] - The company will also receive a tiered sales royalty on future net sales of LAE002 in the licensed regions, with rates ranging from over ten percent to over twenty percent [1]
来凯医药：与齐鲁制药订立独家许可协议，最高可获20.45亿元首付款及里程碑款项